NCT01791725View on ClinicalTrials.gov

A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia

PHASE2CompletedINTERVENTIONAL

Enrollment

23

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions

Down Syndrome

Interventions

DRUG

ELND005

DRUG

Placebo

Trial Locations (3)

92868

University of California, Irvine, Orange

92093-0949

University of California, San Diego, La Jolla

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

Elan Pharmaceuticals

All Listed Sponsors

collaborator

Elan Pharmaceuticals

INDUSTRY

lead

OPKO Health, Inc.

INDUSTRY